FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1796787464> ?p ?o ?g. }

• W1796787464 endingPage "3508" @default.
• W1796787464 startingPage "3502" @default.
• W1796787464 abstract "PURPOSE To evaluate the influence of cumulative dose, dose-intensity, single-dose level, and schedule of epirubicin on the risk of developing congestive heart failure (CHF) in patients with advanced breast cancer. PATIENTS AND METHODS Four hundred sixty-nine consecutive anthracyline-naive patients with metastatic breast cancer were included. Only patients with cardiac failure according to New York Heart Association (NYHA) function class II or more were recorded as having CHF. For each patient, the following were calculated: the cumulative dose of epirubicin, mean dose-intensity (cumulative dose of epirubicin/duration of treatment), and single-dose level (cumulative dose of epirubicin/number of injections). RESULTS Thirty-four patients (7.2%) developed CHF. The cumulative risk of cardiotoxicity was 4% at 900 mg/m2 and increased exponentially to 15% at 1,000 mg/m2. Irradiation against the mediastinum and thoracic spine increased the risk of CHF (P=.025), but dose-intensity, single-dose level, and schedule had no influence on the risk of developing CHF. Age, previous adjuvant irradiation (to the left or right hemithorax), and previous chemotherapy (cyclophosphamide, methotrexate, and fluorouracil [CMF]) were not risk factors. The median time to onset of CHF following the last dose of epirubicin was 57 days (range, 0 to 853). Among patients with CHF, 13 (38.2%) died of cardiac failure. The median survival time for all patients with CHF was 162 days (range, 0 to +1,957). Previous irradiation directly against the heart increased the risk of death due to cardiac failure and decreased the median survival time to 125 days (range, 0 to 336). CONCLUSION The present large retrospective study of 469 patients substantiates previous results concerning the cardiotoxicity of epirubicin. A significantly increasing risk of CHF in patients who receive cumulative doses greater than 950 mg/m2 was established. The future recommended maximum cumulative dose of epirubicin should be 900 mg/m2 in patients with metastatic breast cancer. Previous irradiation against the heart leads to an increased risk of developing CHF with an accelerated course to death, which indicates an additive cardiotoxic effect of irradiation and epirubicin." @default.
• W1796787464 created "2016-06-24" @default.
• W1796787464 creator A5004947197 @default.
• W1796787464 creator A5011312455 @default.
• W1796787464 creator A5035132667 @default.
• W1796787464 creator A5045716792 @default.
• W1796787464 creator A5052286535 @default.
• W1796787464 creator A5090876784 @default.
• W1796787464 date "1998-11-01" @default.
• W1796787464 modified "2023-10-18" @default.
• W1796787464 title "Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer." @default.
• W1796787464 cites W119184795 @default.
• W1796787464 cites W120612427 @default.
• W1796787464 cites W1490689070 @default.
• W1796787464 cites W1828224642 @default.
• W1796787464 cites W1888375872 @default.
• W1796787464 cites W1899365042 @default.
• W1796787464 cites W1936178215 @default.
• W1796787464 cites W1969709647 @default.
• W1796787464 cites W1980952418 @default.
• W1796787464 cites W1982230933 @default.
• W1796787464 cites W1993672158 @default.
• W1796787464 cites W1998260358 @default.
• W1796787464 cites W2003541263 @default.
• W1796787464 cites W2030264882 @default.
• W1796787464 cites W2030843830 @default.
• W1796787464 cites W2044031016 @default.
• W1796787464 cites W2054084477 @default.
• W1796787464 cites W2079349522 @default.
• W1796787464 cites W2090101539 @default.
• W1796787464 cites W2158747369 @default.
• W1796787464 cites W2264393638 @default.
• W1796787464 cites W2265230738 @default.
• W1796787464 cites W2305791584 @default.
• W1796787464 cites W2399481698 @default.
• W1796787464 cites W2472770723 @default.
• W1796787464 cites W2796782673 @default.
• W1796787464 doi "https://doi.org/10.1200/jco.1998.16.11.3502" @default.
• W1796787464 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9817267" @default.
• W1796787464 hasPublicationYear "1998" @default.
• W1796787464 type Work @default.
• W1796787464 sameAs 1796787464 @default.
• W1796787464 citedByCount "261" @default.
• W1796787464 countsByYear W17967874642012 @default.
• W1796787464 countsByYear W17967874642013 @default.
• W1796787464 countsByYear W17967874642014 @default.
• W1796787464 countsByYear W17967874642015 @default.
• W1796787464 countsByYear W17967874642016 @default.
• W1796787464 countsByYear W17967874642017 @default.
• W1796787464 countsByYear W17967874642018 @default.
• W1796787464 countsByYear W17967874642019 @default.
• W1796787464 countsByYear W17967874642020 @default.
• W1796787464 countsByYear W17967874642021 @default.
• W1796787464 countsByYear W17967874642022 @default.
• W1796787464 countsByYear W17967874642023 @default.
• W1796787464 crossrefType "journal-article" @default.
• W1796787464 hasAuthorship W1796787464A5004947197 @default.
• W1796787464 hasAuthorship W1796787464A5011312455 @default.
• W1796787464 hasAuthorship W1796787464A5035132667 @default.
• W1796787464 hasAuthorship W1796787464A5045716792 @default.
• W1796787464 hasAuthorship W1796787464A5052286535 @default.
• W1796787464 hasAuthorship W1796787464A5090876784 @default.
• W1796787464 hasConcept C121608353 @default.
• W1796787464 hasConcept C126322002 @default.
• W1796787464 hasConcept C141071460 @default.
• W1796787464 hasConcept C143998085 @default.
• W1796787464 hasConcept C151032500 @default.
• W1796787464 hasConcept C164705383 @default.
• W1796787464 hasConcept C2776694085 @default.
• W1796787464 hasConcept C2776755627 @default.
• W1796787464 hasConcept C2778198053 @default.
• W1796787464 hasConcept C2778233292 @default.
• W1796787464 hasConcept C2780835546 @default.
• W1796787464 hasConcept C530470458 @default.
• W1796787464 hasConcept C71924100 @default.
• W1796787464 hasConceptScore W1796787464C121608353 @default.
• W1796787464 hasConceptScore W1796787464C126322002 @default.
• W1796787464 hasConceptScore W1796787464C141071460 @default.
• W1796787464 hasConceptScore W1796787464C143998085 @default.
• W1796787464 hasConceptScore W1796787464C151032500 @default.
• W1796787464 hasConceptScore W1796787464C164705383 @default.
• W1796787464 hasConceptScore W1796787464C2776694085 @default.
• W1796787464 hasConceptScore W1796787464C2776755627 @default.
• W1796787464 hasConceptScore W1796787464C2778198053 @default.
• W1796787464 hasConceptScore W1796787464C2778233292 @default.
• W1796787464 hasConceptScore W1796787464C2780835546 @default.
• W1796787464 hasConceptScore W1796787464C530470458 @default.
• W1796787464 hasConceptScore W1796787464C71924100 @default.
• W1796787464 hasIssue "11" @default.
• W1796787464 hasLocation W17967874641 @default.
• W1796787464 hasLocation W17967874642 @default.
• W1796787464 hasOpenAccess W1796787464 @default.
• W1796787464 hasPrimaryLocation W17967874641 @default.
• W1796787464 hasRelatedWork W1128591045 @default.
• W1796787464 hasRelatedWork W2042322799 @default.
• W1796787464 hasRelatedWork W2065081344 @default.
• W1796787464 hasRelatedWork W2090953207 @default.
• W1796787464 hasRelatedWork W2349695038 @default.

• next